About
Greenwich LifeSciences
Corporate Overview
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a clinical-stage public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and has commenced Flamingo-01, a Phase III clinical trial, currently enrolling at up to 150 sites globally. Flamingo-01 is designed to evaluate the safety and efficacy of GLSI-100 in HER2/neu positive patients with residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment.
GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100.
Breast Cancer Statistics
Statistic #1
1 in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 700,000 new breast cancer patients and 9.5 million breast cancer survivors in the U.S. and EU in 2025, all of whom have the potential to experience breast cancer recurrences.
Source: American Cancer Society; Economic Impact, & European Cancer Information System 2025
Statistic #2
HER2/neu positive breast cancer patients comprise approximately 25% of all breast cancer patients.
Source: American Society of Clinical Oncology
Breast Cancer Statistics
Statistic #1
1 in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 700,000 new breast cancer patients and 9.5 million breast cancer survivors in the U.S. and EU in 2025, all of whom have the potential to experience breast cancer recurrences.
Source: American Cancer Society; Economic Impact, & European Cancer Information System 2025
Statistic #2
HER2/neu positive breast cancer patients comprise approximately 25% of all breast cancer patients.
Source: American Society of Clinical Oncology